
Allergen information
This product is free from all 14 major allergens as defined by UK food supplement labelling regulations, including gluten and soya.
Who is this for?
“I first became interested in myo-inositol when I was preparing for IVF. I didn’t have PMOS (formerly PCOS) or insulin resistance, but I was fascinated to find that the research wasn’t limited to women who did.
I chose to include it in my own preconception routine, and when we created ours I wanted to stay close to the research: pure myo-inositol, a 4g daily dose and nothing unnecessary. It’s a simple product, but one with a really interesting and evolving body of research behind it.”
Myo-inositol: what does the research tell us?
Fertility Hero Myo-Inositol provides 4g myo-inositol per day, split into two 2g doses. Research spans PMOS (formerly PCOS), metabolic health, assisted reproduction and male reproductive health.
Myo-inositol is involved in insulin signalling — the process by which cells respond to insulin — and this has made it an important area of research in PMOS, where insulin resistance is common. Clinical studies have investigated inositol in relation to metabolic, hormonal and reproductive markers in women with PMOS.
Clinical trials and systematic reviews have investigated inositol across metabolic, hormonal and reproductive outcomes in women with PMOS. Some studies have reported improvements in measures of insulin resistance, glucose and androgen levels and menstrual-cycle regularity, although results vary between studies and the overall evidence continues to evolve.
Myo-inositol is naturally present in follicular fluid, which surrounds the developing egg. It has been studied in women undergoing IVF, including women both with and without PMOS, with researchers looking at ovarian stimulation, oocyte maturity and other assisted-reproduction outcomes.
Clinical trials and meta-analyses have investigated myo-inositol before and during ovarian stimulation. Research has reported findings including reduced gonadotropin requirements and, in some analyses, a higher proportion of mature oocytes. Results for embryo quality, pregnancy and other IVF outcomes are mixed, making this an interesting and still developing area of fertility research.
Myo-inositol isn't only being studied in women. It is naturally present in the male reproductive system, and research has investigated supplementation in relation to semen quality and male reproductive health.
A 2024 systematic review and meta-analysis of 16 studies reported associations between myo-inositol supplementation and improvements in total and progressive sperm motility and testosterone levels, alongside a reduction in sperm DNA fragmentation. Male research is less established than the literature in women, but it is an interesting and growing area of study.
Interest in myo-inositol extends beyond fertility. Researchers have also investigated inositol supplementation and metabolic health later in women's lives, including in postmenopausal women.
Studies in postmenopausal women have explored myo-inositol in relation to metabolic markers including insulin resistance and lipid profiles. This research is much less extensive than the literature in PMOS, but it broadens the scientific interest in myo-inositol beyond the preconception years.
